Plasma myeloperoxidase activity as a criterion of therapeutic effectiveness for patients with cardiovascular diseases

• Published in: Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry Biomedical chemistry, 2016-04, Vol.10 (2), p.173-179
• Main Authors: Grigorieva, D. V., Gorudko, I. V., Kostevich, V. A., Sokolov, A. V., Buko, I. V., Vasilyev, V. B., Polonetsky, L. Z., Panasenko, O. M., Cherenkevich, S. N.
• Format: Article
• Language: English
• Subjects: Bioorganic Chemistry; Cardiovascular disease; Chemistry; Chemistry and Materials Science; Drug therapy; Effectiveness studies; Medicinal Chemistry; Plasma
• ISSN: 1990-7508; 1990-7516
• DOI: 10.1134/S1990750816020050

A significant increase in the myeloperoxidase (MPO) activity has been found in plasma of patients with stable angina and with acute coronary syndrome (ACS) in comparison with the control group. MPO concentration was significantly increased in plasma of ACS patients. Reduced MPO activity in the treated ACS patients correlated with a favorable outcome of the disease. Generally, changes in plasma MPO concentration coincided with changes in lactoferrin concentration thus confirming the role of neutrophil degranulation in the increase of plasma concentrations of these proteins. The increase in MPO activity was obviously determined by modification of the MPO protein caused by reactive oxygen species and halogen in the molar ratio of 1: 25 and 1: 50. The decrease in plasma MPO activity may be associated with increased plasma concentrations of the physiological inhibitor of its activity, ceruloplasmin, and also with modification of the MPO protein with reactive oxygen species and halogen at their molar ratio of 1: 100 and higher. Thus, MPO activity may be used for evaluation of effectiveness of the treatment of cardiovascular diseases.